Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Revenue (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Revenue for 8 consecutive years, with $34.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 183.88% year-over-year to $34.1 million, compared with a TTM value of $106.5 million through Dec 2025, up 351.04%, and an annual FY2025 reading of $106.5 million, up 351.04% over the prior year.
  • Revenue was $34.1 million for Q4 2025 at Zevra Therapeutics, up from $26.1 million in the prior quarter.
  • Across five years, Revenue topped out at $34.1 million in Q4 2025 and bottomed at $48000.0 in Q2 2022.
  • Average Revenue over 5 years is $9.7 million, with a median of $4.1 million recorded in 2024.
  • The sharpest move saw Revenue plummeted 99.6% in 2022, then surged 17545.83% in 2023.
  • Year by year, Revenue stood at $2.6 million in 2021, then decreased by 10.19% to $2.3 million in 2022, then soared by 457.14% to $12.9 million in 2023, then fell by 7.03% to $12.0 million in 2024, then skyrocketed by 183.88% to $34.1 million in 2025.
  • Business Quant data shows Revenue for ZVRA at $34.1 million in Q4 2025, $26.1 million in Q3 2025, and $25.9 million in Q2 2025.